PF-06700841
TYK2/JAK1 Inhibitor
Also Known As:
methanone, ((1S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-4-pyrimidinyl)-3,8-diazabicyclo(3.2.1)oct-8-yl)-
Networked: 3
relevant articles (0 outcomes,
2 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Peeva, Elena:
3 articles
(12/2020 - 01/2018)
|
| 2. | Banfield, Christopher:
2 articles
(01/2020 - 01/2018)
|
| 3. | Fensome, Andrew:
2 articles
(01/2020 - 01/2018)
|
| 4. | Kieras, Elizabeth:
2 articles
(01/2020 - 01/2018)
|
| 5. | Page, Karen M:
2 articles
(01/2020 - 01/2018)
|
| 6. | Scaramozza, Matthew:
2 articles
(01/2020 - 01/2018)
|
| 7. | Zhang, Weidong:
2 articles
(01/2020 - 01/2018)
|
| 8. | Forman, Seth B:
1 article
(12/2020)
|
| 9. | Gilbert, Steven A:
1 article
(12/2020)
|
| 10. | Kieras, Elizabeth M:
1 article
(12/2020)
|
Related Diseases
| 1. | Psoriasis (Pustulosis Palmaris et Plantaris)
12/01/2020
- " We report results from a phase IIa study of efficacy and safety of PF-06700841, an oral TYK2/Jak1 inhibitor, in patients with moderate-to-severe plaque psoriasis (NCT02969018). " 12/01/2020
- " TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial." 01/01/2018
- " The safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06700841 were assessed in a randomized, double-blind, placebo-controlled, single- and multiple-dose escalation, parallel-group study in healthy subjects and patients with plaque psoriasis. " 12/01/2020
- " PF-06700841 was generally effective and well tolerated in patients with moderate-to-severe plaque psoriasis." 01/01/2020
- " Patients (n = 30) with moderate-to-severe psoriasis were randomized to once-daily 30 mg (n = 14) or 100 mg (n = 7) PF-06700841 or placebo (n = 9) for 28 days. "
|
| 2. | Inflammation (Inflammations)
|
|
Related Drugs and Biologics